Diagnostic significance of matrix metalloproteinases in predicting one-year mortality in liver cirrhosis
https://doi.org/10.31146/1682-8658-ecg-230-10-107-113
Abstract
Aim of the investigation. To study the significance of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in combination with markers of liver pathology in predicting one-year mortality in patients with liver cirrhosis. Materials and methods. Over the course of one year of follow-up, 159 patients with liver cirrhosis aged 26 to 64 years were examined. The primary endpoint was assessed: death from any cause. The blood levels of MMP-1, MMP-9, and TIMP-1 were determined by enzyme-linked immunosorbent assay. Results. One-year mortality was 8.5% and it was associated with parameters of Child-Pugh score ≥8 points, C-reactive protein ≥15.5 mg/l, ESR ³12 mm/hour, gammaglutamyltranspeptidase ≥124 u/l, prothrombin index ≤77%, albumin ≤30 g/l, MMP-1 ≥24.2 ng/ml, MMP-9 ≥331 ng/ml, TIMP-1/MMP-1 ≤19.4, TIMP-1/MMP-9 ≤2.4, with the presence of alcoholic etiology, inflammatory syndrome, ascites 2-3rd degree. According to multivariate regression analysis, the independent factors of one-year mortality in liver cirrhosis were Child-Pugh score and TIMP-1/MMR-9 ratio. The combination of these signs in predicting a lethal outcome had a sensitivity of 92.3% and a specificity of 84.3% (AUC 0.890). Conclusion. Thus, Child-Pugh score and TIMP-1/MMP-9 ratio are predictors of one-year mortality in patients with liver cirrhosis, which reflects the severity of liver damage and the development of complications, as well as due to the participation of MMP-9 in inflammation and vascular remodeling.
About the Authors
A. V. Yagoda
Stavropol State Medical University
Russian Federation
Russian Federation
P. V. Koroy
Stavropol State Medical University
Russian Federation
Russian Federation
T. R. Dudov
Stavropol State Medical University
Russian Federation
Russian Federation
References
1. Wu X.-N., Xue F., Zhang N. et al. Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019. BMC Public Health. 2024; 24: 363. doi: 10.1186/s12889-024-17948-6.
2. Asrani S. K., Devarbhavi H., Eaton J., Kamath P.S. Burden of liver diseases in the world. J. Hepatol. 2019; 70: 151-171. doi: 10.1016/j.jhep.2018.09.014.
3. Sepanlou S. G., Safiri S., Bisignano C. et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 2020; 5 (3): 245-266. doi: 10.1016/S2468-1253(19)30349-8.
4. Cheemerla S., Balakrishnan M. Global epidemiology of chronic liver disease. Clin. Liver Dis. (Hoboken). 2021; 17 (5): 365-370. doi: 10.1002/cld.1061.
5. Ye F., Zhai M., Long J. et al. The burden of liver cirrhosis in mortality: results from the global burden of disease study. Front. Public Health. 2022; 10: 909455. doi: 10.3389/fpubh.2022.909455.
6. Hagström H., Lindfors A., Holmer M. et al. Etiologies and outcomes of cirrhosis in a large contemporary cohort. Scand. J. Gastroenterol. 2021; 56 (6): 727-732. doi: 10.1080/00365521.2021.1912167.
7. Mallik M., Singhai A., Khadanga S. et al. The significant morbidity and mortality indicators in patients of cirrhosis. Cureus. 2022; 14 (1): e21226. doi: 10.7759/cureus.21226.
8. Peng Y., Qi X., Guo X. Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Medicine (Baltimore). 2016; 95: e2877. doi: 10.1097/MD.0000000000002877.
9. Koroy P. V., Dudov T.R., Yagoda A.V., Sarithala V.J. Matrix metalloproteinases: the role in evolution of liver diseases. Medical News of North Caucasus. 2023; 18 (2): 219-225. doi: 10.14300/mnnc.2023.18052.
10. Dudov T. R., Koroy P.V., Yagoda A.V.Complications of liver cirrhosis and matrix metalloproteinases: clinical relationships. Medical News of North Caucasus. 2023; 18 (4): 363-367. (In Russ.) doi: 10.14300/mnnc.2023.18086.@@ Дудов Т.Р., Корой П.В., Ягода А.В. Осложнения цирроза печени и матриксные металлопротеиназы: клинические взаимосвязи. Медицинский вестник Северного Кавказа. 2023; 18 (4): 363-367. doi: 10.14300/mnnc.2023.18086.
11. Huang C.-Y., Tseng K.-C., Lin M.-N. et al. Plasma levels of matrix metalloproteinase-2 and -9 in male and female patients with cirrhosis of different aetiologies. J. Clin. Pathol. 2015; 68: 917-922. doi: 10.1136/jclinpath-2015-202932.
12. Metwally K., Fouad T., Shible N. et al. Metalloproteinase inhibitor-1 closely correlates with the severity of liver disease in Egyptian patients. J. Liver Disease Transplant. 2017; 6 (4): 1000157. doi: 10.4172/2325-9612.1000157.
13. Prystupa A., Boguszewska-Czubara A., Bojarska-Junak A. et al. Activity of MMP-2, MMP-8 and MMP-9 in serum as a marker of progression of alcoholic liver disease in people from Lublin Region, eastern Poland. Ann. Agric. Environ. Med. 2015; 22: 325-328. doi: 10.5604/12321966.1152088.
14. Nilsson E., Anderson H., Sargenti K. et al. Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients. Aliment. Pharmacol. Ther. 2019; 49: 1421-1430. doi: 10.1111/apt.15255.
15. Petkau V. V., Bessonova E.N., Breder V.V., Karimova A.A. Overall survival of patients with liver cirrhosis. Medical News of North Caucasus. 2023; 18 (3): 257-260. (In Russ.) doi: 10.14300/mnnc.2023.18060.@@ Петкау В.В., Бессонова Е.Н., Бредер В.В. и др. Общая выживаемость пациентов с циррозом печени. Медицинский вестник Северного Кавказа. 2023; 18 (3): 257-260. doi: 10.14300/mnnc.2023.18060.
16. Gani R.A. Survival analysis of hospitalized liver cirrhotic patients in Jakarta: 2 years follow up study. Indones. J. Gastroenterol. Hepatol. Dig. Endosc. 2021; 22 (1): 9-15.
17. Hasan I., Nababan S.H. H., Handayu A.D. et al. Scoring system for predicting 90-day mortality of in-hospital liver cirrhosis patients at Cipto Mangunkusumo Hospital. BMC Gastroenterology. 2023; 23: 190. doi: 10.1186/s12876-023-02813-4
18. Kartoun U., Corey K.E., Simon T.G. et al. The MELD-Plus: a generalizable prediction risk score in cirrhosis. PLoSONE. 2017; 12 (10): e0186301. doi: 10.1371/journal.pone.0186301.
19. Marciano S., Diaz J.M., Dirchwolf M., Gadano A. Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies. Hepat. Med. 2019; 11: 13-22. doi: 10.2147/HMER.S164250.
20. Lam S., Singh R., Dillman J.R. et al. Serum matrix metalloproteinase 7 is a diagnostic biomarker of biliary injury and fibrosis in pediatric autoimmune liver disease. Hepatology Communications. 2020; 4 (11): 1680-1693. doi: 10.1002/hep4.1589.
21. Hori T., Uemoto S., Walden L.B. et al. Matrix metalloproteinase-9 as a therapeutic target for the progression of fulminant liver failure with hepatic encephalopathy: a pilot study in mice. Hepatol. Res. 2014; 44: 651-662. doi: 10.1111/hepr.12161.
22. Kwon O. S., Jung H.S., Bae K.S. et al. Increased serum activity of matrix metalloproteinase-9 in patients with acute variceal bleeding. Gut Liver. 2012; 6 (2): 249-255. doi: 10.5009/gnl.2012.6.2.249.
23. Irvine K.M., Okano S., Patel P.J.L. et al. Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease. Sci. Rep. 2021; 11 (1): 2858. doi: 10.1038/s41598-021-82315-z.
24. Wu J.-F., Jeng Y.-M., Chen H.-L. et al. Quantification of serum matrix metallopeptide 7 levels may assist in the diagnosis and predict the outcome for patients with biliary atresia. J. Pediatr. 2019; 208: 30-37. doi: 10.1016/j.jpeds.2018.12.006.
25. Somuncu M. U., Pusuroglu H., Karakurt H. et al. The prognostic value of elevated matrix metalloproteinase-9 in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a two-year prospective study. Rev. Port. Cardiol. 2020; 39 (5): 267-276. doi: 10.1016/j.repc.2019.09.011.
26. Zhu S., Waili Y., Qi X. et al. Lymphocyte-monocyte ratio at admission predicts possible outcomes in patients with acute-on-chronic liver failure. Eur. J. Gastroenterol. Hepatol. 2017, 29: 31-35. doi: 10.1097/MEG.0000000000000767.
27. de Souza P., Schulz R., da Silva-Santos J.E. Matrix metalloproteinase inhibitors prevent sepsis-induced refractoriness to vasoconstrictors in the cecal ligation and puncture model in rats. Eur. J. Pharmacol. 2015; 765: 164-170. doi: 10.1016/j.ejphar.2015.08.030.
28. Yan L., Wang J., Hu X. et al. Imbalance in matrix metalloproteinases and tissue inhibitor of metalloproteinases from splenic veins and great saphenous veins under high hemodynamics. Phlebology. 2020; 35 (1): 18-26. doi: 10.1177/0268355519842432.
29. Yagoda A. V., Koroy P.V., Dudov T.R. Matrix metalloproteinases and morphological features in chronic liver diseases. Experimental and Clinical Gastroenterology. 2023; 218 (10): 153-159. (In Russ.) doi: 10.31146/1682-8658-ecg-218-10-153-159.@@ Ягода А.В., Корой П.В., Дудов Т.Р. Матриксные металлопротеиназы и морфологическая картина при хронических заболеваниях печени. Экспериментальная и клиническая гастроэнтерология. 2023; 218 (10): 153-159. doi: 10.31146/1682-8658-ecg-218-10-153-159.
30. Wang X., Maretti-Mira A. C., Wang L., Deleve L.D. Liver-selective MMP-9 inhibition in the rat eliminates ischemia-reperfusion injury and accelerates liver regeneration. Hepatology. 2019; 69: 314-328. doi: 10.1002/hep.30169.
Review
For citations:
Yagoda A.V., Koroy P.V., Dudov T.R. Diagnostic significance of matrix metalloproteinases in predicting one-year mortality in liver cirrhosis. Experimental and Clinical Gastroenterology. 2024;(10):107-113. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-230-10-107-113
Views:
8
Email this article 